Clinical Trials Browser

Phase 2 × mirdametinib × CNS × Clear all

NCT07237100 2025-11-19

Mirdametinib in Patients With Advanced NF1-mutant Melanoma

Phase 2 Recruiting

CNSDermatologic

Melanoma, Neurofibromatoses

NCT03962543 2025-08-07

ReNeu

Phase 2 Active not recruiting

114 enrolled 25 charts 1 FDA

Neurofibroma, Neurofibromatosis 1, Neurofibromatoses, Neurofibroma, Plexiform

NCT02096471 2019-01-10

MEK Inhibitor

Phase 2 Completed

19 enrolled 14 charts

Neurofibroma, Neurofibromatosis 1